What does the LOBO® HD BRAID® Vascular Occluder cost?

Practical pricing guidance for a proprietary peripheral embolization system

The LOBO® Vascular Occlusion System received FDA 510(k) clearance starting in November 2019, with the LOBO-7 and LOBO-9 sizes cleared in June 2022.

The system comprises four models: LOBO-3, LOBO-5, LOBO-7, and LOBO-9 , each designed for a specific vessel diameter range. Despite this FDA clearance and clinical adoption, public pricing for the LOBO occluders does not appear in GSA contracts, major group purchasing organizations (GPOs), or medical device pricing databases as of May 2026. Okami Medical, a privately held company, maintains direct sales channels and does not publish list pricing. This article will be updated as MedSource collects proprietary quote data from healthcare providers.

What the typical range likely is

Industry comparables suggest LOBO® occluders trade in the mid-to-premium price band within vascular embolization devices. The global occlusion devices market was valued at USD 6.44 billion in 2025 and is projected to grow to USD 13.24 billion by 2034. Traditional embolic alternatives—coils and plugs—typically range from $800 to $3,500 per unit depending on size and material; braided devices generally command prices at the upper end of that spectrum. Procurement officers should expect the LOBO occluders to fall in the $1,200–$3,200 per device range on initial quotes, with variation driven by:

• Vessel size (LOBO-3 vs. LOBO-9 likely differ by $300–$600)
• Delivery catheter bundle (whether SENDERO microcatheters are bundled or purchased separately)
• Purchase volume and multi-year agreements
• Regional sales territory and distributor margins

This estimate is preliminary and based on comparable braided occluders in the market; actual pricing requires direct negotiation with Okami's sales team.

What pushes price up — features, certifications, support tier

The LOBO occluder is the first and only peripheral embolization device featuring proprietary HDBRAID® technology – an innovative, unique braiding method developed specifically for making devices to occlude vessels.

HDBRAID™ technology offers four times greater pore density and smaller pores than standard braiding methods, and the pore structure helps significantly reduce blood flow to a target location, thereby accelerating haemostasis and thrombosis. This patented manufacturing process justifies premium pricing versus conventional braided coils.

Single-device efficiency: The device achieves 90 seconds average time to occlusion with a single device in a wide range of cases. Reducing the number of devices per procedure lowers overall procedure cost—but also concentrates risk on the occluder's performance, which may drive higher per-unit pricing.

MRI compatibility: The product is MR Conditional, with patients able to undergo MRI safely in systems of 1.5-Tesla and 3-Tesla field strengths. This feature eliminates post-implant imaging restrictions and may command a premium in centers with high-volume MRI utilization.

Indication breadth: The LOBO-3 is intended for 1.5mm to 3mm diameter vessels, LOBO-5 for 3mm to 5mm, LOBO-7 for 5mm to 7mm, and LOBO-9 for 7mm to 9mm vessels. Larger sizes (LOBO-7 and LOBO-9) almost certainly carry higher prices due to increased material and complexity.

Installation and training: As a young product with proprietary mechanics, Okami likely bundles onsite training and technical support with initial orders. These services increase acquisition cost but reduce deployment risk.

What pushes price down — refurbished, older generation, lease, GPO contracts

At present, no secondary market for used LOBO occluders is documented, and Okami Medical does not advertise refurbished inventory. Given the device's relative newness (2019 launch), no older "generation 1" clearance exists to be discounted against newer models.

GPO and group purchasing leverage: Large healthcare systems should request quotes under existing vascular embolization or interventional device GPO contracts. Okami's relationship with national GPOs (e.g., Medline Industries, Henry Schein GPO) will determine negotiated tiers. If Okami has not yet signed GPO master agreements, direct-purchase volume discounts should be negotiated at 10–20% off list for multi-year commitments.

Bundled system pricing: Purchasing LOBO occluders alongside the SENDERO Microcatheter or SENDERO MAX Delivery Catheter (both intended for peripheral vasculature infusion) in a single contract may unlock package discounts unavailable for device-only orders.

Lease or revenue-share models: No information on Okami lease programs is publicly available. Contact the sales team directly to negotiate consignment or procedure-based pricing if suitable for your procedural volume.

Hidden costs — install, training, calibration, consumables, service contracts

Delivery catheters: The LOBO occluder is a low-profile embolic device that is microcatheter compatible. The SENDERO microcatheters are sold separately, not bundled. Budget $200–$500 per catheter; a typical case may require one to two catheters.

Storage and inventory: Occluders are single-use, sterile devices. Stock sufficient inventory to avoid stock-outs but not so much that expiration losses accumulate. Okami's typical shelf life should be confirmed (typically 3–5 years for braided devices).

Operator training: Interventional radiologists and cardiologists using LOBO for the first time require manufacturer-led training on deployment mechanics, device limits (no crush/bend forces in joint areas), and complication management. Budget $5,000–$15,000 for on-site training and proctoring for a new center.

Service contracts: No data on Okami's post-sale support agreements (e.g., technical hotline, complication response) is published. Standard expectation for a private manufacturer would be inclusion of 12 months of technical support; renewal contracts typically cost 5–10% of purchase price annually.

Regulatory and documentation: Ensure compliance with institutional implant registries and adverse event reporting. Minimal cost but requires administrative workflow integration.

How to negotiate — concrete tactics

1. Request a competitive evaluation against coils (e.g., Cook Embolization Coils) and plugs (e.g., Abbott Amplatzer, Cook ArtemisFlex). Document clinical outcomes in your patient population to justify LOBO's higher per-unit cost if it reduces number of devices used per case.

2. Lock in volume tiers: Commit to a minimum annual unit purchase (e.g., 200–500 occluders) in exchange for 15–25% discount and extended payment terms.

3. Negotiate catheter pricing separately: SENDERO catheters may be purchased from third-party distributors; don't accept bundled-only pricing.

4. Request extended payment terms (60–90 days) and consignment inventory for the first 90 days to reduce upfront capital requirements.

5. Benchmark against academic medical centers using LOBO. Request references and ask about realized pricing; most centers will disclose ballpark figures (though not exact contracts).

6. Consolidate within your supply agreement: If your institution purchases other Okami products (e.g., SENDERO catheters), negotiate system-wide pricing.

When the price feels off — red flags

• Lack of transparency from Okami: A private company unwilling to provide written quotes or reference pricing is a warning. Request formal quotes in writing and establish a 30-day ceiling for responses.

• GPO-exclusive or sole-distributor agreements: Beware of terms that lock you into one regional distributor without competitive alternatives. Okami's distribution model should be clarified before contract signing.

• No volume discounts offered: If Okami quotes the same unit price for 50 devices as for 500, they are either padding margins or undervaluing your commitment.

• Expiration dates on older inventory: Ask for device manufacturing dates and lot numbers at purchase. Avoid lots approaching expiration; insist on at least 36 months of remaining shelf life.

• Training contingencies: If on-site training is promised but not included in the written contract, negotiate terms in advance. Don't accept verbal assurances.

• Catheter compatibility restrictions: Verify in writing that SENDERO catheters are compatible with alternative microcatheter platforms (e.g., Penumbra, Merit Medical). Some occluder systems are locked to proprietary delivery systems, raising long-term costs.

Sources

• Okami Medical. "LOBO Vascular Occlusion System – Technology Overview." https://okamimedical.com/lobo-technology/.
• Okami Medical. "FDA 510(k) Clearance and Patent Issuance Press Release." November 4, 2019.
• Okami Medical. "LOBO-7 and LOBO-9 FDA 510(k) Clearance Press Release." June 7, 2022.
• Endovascular Today. "Okami Medical's LOBO-7 and LOBO-9 Vascular Occluders Receive FDA Clearance." June 7, 2022.
• Medical Device Network. "Okami Medical's LOBO Vascular Occlusion System, US." July 2022.

---

Note: This article reflects publicly available information as of May 2026. Pricing will be updated as MedSource compiles proprietary quotes from hospital procurement departments and group purchasing organizations. Contact Okami Medical directly at okamimedical.com or request a pricing consultation to obtain current institutional pricing.